These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915 [TBL] [Abstract][Full Text] [Related]
5. [Meloxicam-induced colitis revealed by acute abdominal pain]. Seddik H; Rabhi M Ann Pharm Fr; 2013 Mar; 71(2):119-22. PubMed ID: 23537413 [TBL] [Abstract][Full Text] [Related]
6. Acute cholestatic hepatitis associated with celecoxib. Grieco A; Miele L; Giorgi A; Civello IM; Gasbarrini G Ann Pharmacother; 2002 Dec; 36(12):1887-9. PubMed ID: 12452750 [TBL] [Abstract][Full Text] [Related]
7. Prolonged cholestasis associated with short-term use of celecoxib. Chamouard P; Walter P; Baumann R; Poupon R Gastroenterol Clin Biol; 2005 Dec; 29(12):1286-8. PubMed ID: 16518289 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of celecoxib in the treatment of acute pain due to ankle sprain in a Latin American and Middle Eastern population. Cardenas-Estrada E; Oliveira LG; Abad HL; Elayan F; Khalifa N; El-Usseini T J Int Med Res; 2009; 37(6):1937-51. PubMed ID: 20146894 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Huang WF; Hsiao FY; Wen YW; Tsai YW Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003 [TBL] [Abstract][Full Text] [Related]
10. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Goldstein JL; Cryer B; Amer F; Hunt B Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545 [TBL] [Abstract][Full Text] [Related]
11. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Soni P; Shell B; Cawkwell G; Li C; Ma H Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981 [TBL] [Abstract][Full Text] [Related]
12. By the way, doctor. Celebrex and bleeding. Komaroff A Harv Health Lett; 2008 May; 33(7):8. PubMed ID: 18700242 [No Abstract] [Full Text] [Related]
13. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563 [TBL] [Abstract][Full Text] [Related]
14. Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance. Andri L; Falagiani P Allergol Immunopathol (Madr); 2007; 35(4):126-9. PubMed ID: 17663920 [TBL] [Abstract][Full Text] [Related]
15. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469 [TBL] [Abstract][Full Text] [Related]
16. [Hypersensitivity to celecoxib]. Fradet G; Robin-Le Nechet A; Huguenin H; Chiffoleau A Ann Med Interne (Paris); 2003 May; 154(3):181-2. PubMed ID: 12910047 [TBL] [Abstract][Full Text] [Related]
17. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964 [TBL] [Abstract][Full Text] [Related]